23andMe Internal Communication Presentation Deck

Made public by

sourced by PitchSend

12 of 14

Creator

23andMe logo
23andMe

Category

Healthcare

Published

February 2021

Slides

Transcriptions

#1X₂ 23andMe Employee Option Presentation February 19, 2021 ww 1 WW VE#2This presentation is not intended as tax advice. Please consult your personal tax advisor. Copyright © 2021 23andMe, Inc. 23andMe 2#3Forward-Looking Statements This communication contains certain "forward-looking statements" including statements regarding the anticipated timing and benefits of the merger (the "Transaction") between VG Acquisition Corp. ("VG") and 23andMe, Inc. ("23and Me"). The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intends", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "would" and similar expressions may identify forward looking statements, but the absence of these words does not mean that a statement is not forward looking. The forward-looking statements contained herein are based on 23andMe's current expectations and beliefs concerning future developments and their potential effects, but there can be no assurance that these will be as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of 23and Me) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These factors include, among others: the inability to complete the Transaction; the inability to recognize the anticipated benefits of the proposed Transaction, including due to the failure to receive required security holder approvals, or the failure of other closing conditions; and costs related to the proposed Transaction. Except as required by law, VG and 23andMe do not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Additional Information VG intends to file with the SEC a registration statement on Form S-4, which will include a preliminary proxy statement of VG and a prospectus. The definitive proxy statement and other relevant documents will be mailed to stockholders of VG as of a record date to be established for voting on the business combination. Shareholders of VG and other interested persons are advised to read, when available, the preliminary proxy statement, and amendments thereto, and the definitive proxy statement because these documents will contain important information about VG, 23andMe and the Transaction. Shareholders will also be able to obtain copies of the registration statement and the proxy statement/prospectus, without charge, by directing a request to: VG Acquisition Corp. 65 Bleecker Street, 6th Floor, New York NY 10012. These documents, once available, and VG's annual and other reports filed with the SEC can also be obtained, without charge, at the SEC's internet site (http://www.sec.gov). This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Participants in the Solicitation VG, 23andMe and their respective directors, executive officers, other members of management and employees may be deemed to be participants in the solicitation of proxies from VG's shareholders in connection with the Transaction. Information regarding the names and interests in the proposed transaction of VG's directors and officers is with the SEC. Additional information regarding the interests of such potential participants in the solicitation process will also be included in the registration statement (and will be included in the definitive proxy statement/prospectus) and other relevant documents when they are filed with the SEC. Copyright © 2021 23andMe, Inc. 23andMe 3#4What We Will Cover Glossary of Terms What Happens to Options in the Merger? How Many Options Will I Get in "New" 23andMe? ● • ● Examples Frequently Asked Questions Next Steps Copyright © 2021 23andMa, Inc. 23andMe* 4#5Glossary of Terms Stock Option: the right to buy a specific number of shares of company stock at a pre-set price for a pre-set period of time Shares: a share of stock is a unit of ownership in a company. Investors who hold shares of a company are known as shareholders Strike Price: the pre-set price that must be paid to exercise a stock option and buy the underlying share of stock Merger: the business combination between VGAC and 23andMe, in which your options in 23and Me will become options to buy shares of "new" 23andMe, which will be a public comp Copyright © 2021 23andMa, Inc. 23andMe 5#6What Happens to Options in the Merger? • No difference between vested and unvested options - this is a recent change to our merger agreement that simplifies the process, allowing employees freedom to decide when and whether to exercise options o All vested options will automatically become vested options in "new" 23andMe All unvested options will automatically become unvested options in "new" 23andMe This automatic "rollover" of old options into new options is not taxable • No changes to vesting schedules and expiration dates Copyright © 2021 23andMa, Inc. 23andMe 6#7How Many Options Will I Get in "New" 23andMe? • Your old options will be rolled over into options in "new" 23andMe • The math is the same math that governs the exchange of old 23and Me shares for "new" 23andMe shares in the merger Your "new" options will have the same value as your old options, calculated on the same ratio that applies to 23andMe shares • That ratio will be approximately 2.31 "new" 23andMe options for each old 23andMe option. This translates to a value per share of old 23andMe of $23.11 To match the same value as your old options, your old strike price per share will be divided by 2.31. This means the aggregate strike price of all your old options will exactly match the aggregate strike price of all your "new" options • While 2.31 is approximate, the actual ratio should not change much. It's based on the actual number of outstanding shares plus vested options on the closing date of the merger Copyright © 2021 23andMa, Inc. 23andMe* 7#8Options Example 1 - Strike Price @ $11.57 My Stock Options @ $11.57 Options Strike Price Total Option Strike Price NOTE: These are estimates only, actual calculations may vary Old Options 1,000 $ 11.57 $ 11,570 Conversion x 2.31 + 2.31 New Options 2,310 $ 5.01 $ 11,570 Copyright © 2021 23andMa, Inc. 23andMe* 8#9Options Example 2 - Strike Price @ $6.79 My Stock Options @ $6.79 Options Strike Price Total Option Strike Price NOTE: These are estimates only, actual calculations may vary Old Options 1,000 $6.79 $ 6,790 Conversion x 2.31 + 2.31 New Options 2,310 $2.94 $ 6,790 Copyright © 2021 23andMa, Inc. 23andMe 9#10Reminder • Shares (including shares you buy when you exercise options) cannot be traded until the lockup period ends, which is 180 days after the merger closes • We intend to adopt a public company insider trading policy in connection with the merger closing, which will include blackout periods, and any trade with respect to "new" 23and Me shares will be subject to that policy and any other applicable legal rules . This is all still contingent upon the merger closing! Copyright © 2021 23andMa, Inc. 23andMe 10#11Frequently Asked Questions Q: Can I exercise my stock options now? A: Yes, if you would like to do so. However, in order to exercise your options, you must pay the strike price in cash, plus any applicable withholding taxes (which will generally apply to non-qualified options). Q: Will I have a tax obligation when my old options roll over into "new" 23andMe options? A: No. Copyright © 2021 23andMa, Inc. 23andMe 11#12Frequently Asked Questions Q: What vesting terms will apply to my "new" 23andMe options? A: All vesting terms and conditions remain the same. Your "new" 23and Me options will be governed by the "new" 23and Me 2021 Equity Incentive Plan, which will become effective when the merger closes. Q: Can I share this math with a financial or tax advisor? A: Yes. If you have any questions with respect to the financial or tax implications of your "new" 23and Me options, please consult your financial or tax advisor. Copyright © 2021 23andMa, Inc. 23andMe 12#13Next Steps • Deliver on our goals Await the close of the transaction As much as possible, we will update you along the way - including helpful Lunch & Learns We are also arranging educational sessions with outside financial consultants to support your planning Copyright © 2021 23andMa, Inc. 23andMe 13

Download to PowerPoint

Download presentation as an editable powerpoint.

Related

Fiscal 3Q Investor Presentation image

Fiscal 3Q Investor Presentation

Healthcare

FY23 Full-Year Results Presentation image

FY23 Full-Year Results Presentation

Healthcare

Healthcare Network P&L Statement and Expansion Projects image

Healthcare Network P&L Statement and Expansion Projects

Healthcare

Accreditation and Quality Assurance Overview image

Accreditation and Quality Assurance Overview

Healthcare

Investment Highlights image

Investment Highlights

Healthcare

Investor Presentation image

Investor Presentation

Healthcare

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update image

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

Healthcare

BioAtla Investor Presentation Deck image

BioAtla Investor Presentation Deck

Healthcare